Manufacturer of Controlled Substances; Notice of Application, 77257 [2011-31771]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 238 / Monday, December 12, 2011 / Notices
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate, 72 FR 3417
(2007). Regarding all other basic classes
of controlled substances, no comments
or objections have been received. DEA
has considered the factors in 21 U.S.C.
823(a) and 952(a) and determined that
the registration of Research Triangle
Institute to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on DSK4TPTVN1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 15,
2011, Johnson Matthey Pharma
Services, 70 Flagship Drive, North
Andover, Massachusetts 01845, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Hydrocodone (9193) .....................
VerDate Mar<15>2010
15:55 Dec 09, 2011
II
II
II
Jkt 226001
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–31771 Filed 12–9–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
[FR Doc. 2011–31767 Filed 12–9–11; 8:45 am]
Drug
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 10, 2012.
By Notice dated August 10, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51400,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambridge Isotope Lab to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Cambridge Isotope Lab to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
77257
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–31774 Filed 12–9–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated August 10, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51401, Chemica,
316 West 130th Street, Los Angeles,
California 90061, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Methamphetamine (1105), a basic class
of controlled substance listed in
schedule II.
The above listed controlled substance
is an intermediate in the manufacture of
Benzphetamine, a schedule III nonnarcotic controlled substance. The
company plans to utilize a bulk active
pharmaceutical ingredient (API) as an
intermediate for the development of
another controlled substance, and
further distribution to its customers.
The methamphetamine will not be sold
as a commercial product.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Chemica to manufacture the listed basic
class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Chemica
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 76, Number 238 (Monday, December 12, 2011)]
[Notices]
[Page 77257]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31771]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 15, 2011, Johnson
Matthey Pharma Services, 70 Flagship Drive, North Andover,
Massachusetts 01845, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Hydrocodone (9193)......................... II
------------------------------------------------------------------------
The company plans to utilize this facility to manufacture small
quantities of the listed controlled substances in bulk and to conduct
analytical testing in support of the company's primary manufacturing
facility in West Deptford, New Jersey. The controlled substances
manufactured in bulk at this facility will be distributed to the
company's customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 10, 2012.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-31771 Filed 12-9-11; 8:45 am]
BILLING CODE 4410-09-P
